Targets for antiepileptic drugs in the synapse

Medical Science Monitor

Volumn 13, Issue 1, 2007, Pages

  Landmark, Cecilie Johannessen ^a  

^a OSLO METROPOLITAN UNIVERSITY   (Norway)

Author keywords

Antiepileptic drugs; GABA; Glutamate; Mechanisms of action; Synapse

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BIA 2093; BRIVARACETAM; CARBAMAZEPINE; DIBENZAZEPINE DERIVATIVE; ETIRACETAM; FELBAMATE; FLUOROFELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; NS 1209; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RETIGABINE; SAFINAMIDE; SELETRACETAM; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

APLASTIC ANEMIA; BIPOLAR DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; EPILEPSY; GABAERGIC SYSTEM; HUMAN; INFANTILE SPASM; LIVER FAILURE; MIGRAINE; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE;

ANIMALS; ANTICONVULSANTS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; SYNAPSES;

EID: 33846030193     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Rogawski MA: Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res, 2006; 68: 22-28
2. Spina E, Perugi G: Antiepileptic drugs: indications other than epilepsy. Epileptic disorders 2004; 6: 57-75
3. Rogawski MA, Löscher W: The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nature Medicine, 2004; 10: 685-92
4. Rogawski MA, Löscher W: The neurobiology of antiepileptic drugs. Nature Rev Neuroscience, 2004; 5: 553-64
5. Perucca E: An introduction to antiepileptic drugs. Epilepsia, 2005; 46: 31-37
6. Preece NE, Jackson GD, Houseman JA et al: Nuclear magnetic resonance detection of increased GABA in vigabatrin-treated rats in vivo. Epilepsia, 1994; 35: 431-36
7. Schechter PJ: Clinical pharmacology of vigabatrin. Br J Clin Pharmacol, 1989; 27: 19S-22
8. Kälviäinen R, Nousiainen I: Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs, 2001; 15: 217-30
9. Sills GJ, Patsalos PN, Butler E et al: Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology, 2001; 57: 196-200
10. Krauss GL, Johnson MA, Sheth S, Miller NR: A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurosurg Psychiatry, 2003; 74: 339-43
11. Czuczwar SJ, Patsalos PN: The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs, 2001; 15: 339-50
12. Pollack Mh, Roy-Byrne PP, Van Ameringen M et al: The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry, 2005; 66: 1401-8
13. Löscher W: Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs, 2002; 16: 669-94
14. th ed. Philadelphia: Lippincott Williams & Wilkins, 2002; 767-779
15. Johannessen CU: Mechanisms of action of valproate: a commentary. Neurochem Int, 2000; 37: 103-10
16. Johannessen CU, Petersen D, Fonnum F, Hassel B: The acute effect of valproate on cerebral energy metabolism in mice. Epilepsy Res, 2001; 47: 247-56
17. Löscher W: Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals. Pharm Weekbl Sci, 1992; 14: 139-43
18. Johannessen CU, Johannessen SI: Valproate: Past, Present, and Future. CNS Drug Reviews, 2003; 9: 199-216
19. Johannessen CU, Johannessen SI: An update on valproate: Clinical implications of recent studies for its mechanisms of action. SIIC 2004. Available from: http://www.siicsalud.com/dato/dat038/04707003.htm
20. Harwood AJ, Agam G: Search for a common mechanism of mood stabilizers. Biochem Pharmacol, 2003; 66: 179-89
21. Anmann B, Grunze H: Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia, 2005; 46: 26-30
22. Ju S, Greenberg ML: Valproate disrupts regulation of inositol responsive genes and alters regulation of phospholipid biosynthesis. Mol Microbiol, 2003; 49: 1595-603
23. Brunello N, Tascedda F: Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol, 2003; 6: 181-89
24. Chetcuti A, Adams LJ, Mitchell PB, Schofield PR: Altered gene expression in mice treated with the mood stabilizer sodium valproate. Int J Neuropsychopharmacol, 2005; 28: 1-10
25. Ichikawa J, Chung YC, Dai J, Meltzer HY: Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain Res, 2005; 1052: 56-62
26. Göttlicher M Minucci, S Zhu P et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J, 2001; 20: 6969-78
27. Phiel CJ et al: Histone deacetylases is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem, 2001; 276: 36734-41
28. Dou H, Birusingh K, Faraci J et al: Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci, 2003; 23: 9162-70
29. Yeow WS, Ziauddin MF, Maxhimer JB et al: Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. Br J Cancer, 2006; 22: 1436-45
30. Eyal S, Yagen B, Shimshoni J, Bialer M: Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active constitutional isomers and derivatives. Biochem Pharmacol, 2005; 69: 1501-8
31. Bialer M, Johannessen SI, Kupferberg HJ et al: Progress report on new antiepileptic drugs: a summary of the Seventh Eilat conference (Eilat VII). Epilepsy Res, 2004; 61: 1-48
32. Stratton SC, Large CH, Cox B et al: Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res, 2003; 53: 95-106
33. Lynch B, Lambeng N, Nocka K et al: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci, 2004; 101: 9861-66
34. Poulain P, Margineanu DG: Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neuropharmacol, 2002; 42: 346-52
35. Rigo JM, Hans G, Nguyen L et al: The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol, 2002; 136: 659-72
36. Handforth A, Martin FC: Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord, 2004; 19: 1215-21
37. Bushara KO, Malik T, Exconde RE: The effect of levetiracetam on essential tremor. Neurology, 2005; 64: 1078-80
38. White HS: Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache, 2005; 45: S48-56
39. Kaminski RM, Banerjee M, Rogawski MA: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology, 2004; 46: 1097-104
40. Tiihonen J, Halonen P, Wahlbeck K et al: Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry, 2005; 66: 1012-15
41. + channels in rat hippocampal neurons. Pflügers Arch, 1995; 430: 437-46
42. Liu G, Yarov-Yarovoy V, Nobbs M et al: Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacol, 2003; 44: 413-22
43. + channels. Mol Pharmacol, 1998; 54: 712-21
44. Xie X, Hagan RM: Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology, 1998; 38: 119-30
45. Poolos NP, Migliore M, Johnston D: Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci, 2002; 5: 767-74
46. Ketter TA, Manji HK, Post RM: Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol, 2003; 23: 484-95
47. Muzina DJ, Elhaj O, Gajwani P et al: Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr Scand, 2005; 111: 21-28
48. Ahmad S, Fowler LJ, Whitton PS: Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res, 2005; 63: 141-49
49. Schmidt D, Elger CE: What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav, 2004; 5: 627-35
50. Sills GJ: The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol, 2006; 6: 108-13
51. Marais E, Klugbauer N, Hofman F: Calcium channel alpha(2)delta subunits-structure and gabapentin binding. Mol Pharmacol, 2001; 59: 1243-48
52. Bian F, Li Z, Offord J et al: Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res, 2006; 1075: 68-80
53. Ng GY, Bertrand S, Sullivan R et al: Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol, 2001; 59: 144-52
54. Landy S: Migraine throughout the life cycle. Treatment through the ages. Neurology, 2004; 62: S2-8
55. Kuo CC, Lin BJ, Chang HR, Hsieh CP: Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels. Mol Pharmacol, 2004; 65: 370-80
56. Wallis RA, Panizzon KL, Niquet J et al: Neuroprotective effects of the anticonvulsant, fluorofelbamate. Epilepsia, 2000; 41: 16
57. Schauf CL: Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res, 1987; 413: 185-88
58. Suzuki S, Kawakami K, Nishimura S et al: Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res, 1992; 12: 21-27
59. Mori A, Noda Y, Packer L: The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res, 1998; 30: 153-58
60. Morita S, Miwa H, Kondo T: Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord, 2005; 11: 101-3
61. Tanabe M, Sakaue A, Takasu K et al: Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse. Nauyn Schmiedebergs Arch Pharmacol, 2005; 372: 107-14
62. Wickenden AD, Yu W, Zou A et al: Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol, 2000; 58: 591-600
63. Rundfeldt C, Netzer R: The novel anticonvulsant retigabine activates M-currents in Chineese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett, 2000; 281: 73-76
64. Klitgaard H: Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol Scand, 2005; 181: 68-72
65. Rogawski MA: Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res, 2006; in press
66. Sólyom S, Tarnawa I: Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr Pharm, 2002; 8: 913-39
67. Yee BK, Keist R, von Boehmer L et al: Schizophrenia-related sensorimotor deficit links alpha-3-containing GABAA receptors to a dopamine hyperfunction. Proc Natl Acad Sci, 2005; 22(102): 17154-59
68. A receptor subtype functions. Current Opin Pharmacol, 2006; 6: 18-23
69. Foster AC, Kemp JA: Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol, 2006; 6: 7-17
70. B receptors: a site of therapeutic benefit. Curr Opin Pharmacol, 2006; 6: 37-43
71. Gryder DS, Castaneda DC, Rogawski MA: Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala. J Neurochem, 2005; 94: 1728-38
72. Lynch G: Glutamate-based therapeutic approaches: ampakines. Curr Opin Pharmacol, 2006; 6: 82-88
73. Muir KW: Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol, 2006; 6: 53-60
74. Gogas KR: Glutamate-based approaches: NR2B receptor antagonists. Curr Opin Pharmacol, 2006; 6: 68-74
75. Marino MJ, Conn PJ: Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol, 2006; 6: 98-102
76. Dunlop J: Glutamate-based therapeutic approaches: targeting the glutamate transport system. Curr Opin Pharmacol, 2006; 6: 103-7
77. Rogawski M: Astrocytes get in the act in epilepsy. Nature Medicine, 2005; 11: 919-20
78. Guo-Feng T, Hooman A, Takano T et al: An astrocytic basis of epilepsy. Nature Medicine, 2005; 11: 973-81
79. Seal R, Edwards RH: Functional implications of transmitter co-release: glutamate and GABA share the load. Curr Opin Pharmacol, 2006; 6: 114-19